AMPK: A Target for Drugs and Natural Products With Effects on Both Diabetes and Cancer

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

FIG. 3.
FIG. 3.

Schematic diagram of the proposed new mechanism by which metformin inhibits hepatic gluconeogenesis (42). Up or down arrows next to a metabolite or enzyme show the direction the concentration or activity changes in response to metformin. Metformin (whose uptake into hepatocytes is promoted by the organic cation transporter [OCT1]) accumulates in mitochondria where it inhibits Complex 1 of the respiratory chain, lowering cytoplasmic ATP and increasing ADP and AMP. AMP activates AMPK but also inhibits adenylate cyclase, reducing effects of glucagon on cAMP and PKA and thus reducing the ability of PKA to promote gluconeogenesis by phosphorylation of PFK2 and other targets regulating transcription of gluconeogenic genes. F16BP, fructose-1,6-bisphosphate; F16BPase, fructose-1,6-bisphosphatase; F26BP, fructose-2,6-bisphosphate; G6Pase, glucose-6-phosphatase; PFK1, 6-phosphofructo-1-kinase; PFK2, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase.

This Article

  1. Diabetes vol. 62 no. 7 2164-2172